×
Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 6th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 5th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 6th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 7th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 5th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Avelumab ‘opens up the door’ for immunotherapy in trophoblastic disease
https://www.healio.com/news/hematology-oncology/20200707/avelumab-opens-up-the-door-for-immunotherapy-in-trophoblastic-disease

Jul 6th, 2020 - A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).